MRA Advisory Group Purchases 5,215 Shares of AbbVie Inc. $ABBV

Key Points

• MRA Advisory Group increased its AbbVie stake by 195.5% in the second quarter, purchasing 5,215 additional shares for a total position of 7,883 shares valued at approximately $1.98 million.
• AbbVie reported quarterly EPS of $3.65 and revenue of $16.99 billion, exceeding analyst expectations, while revenue rose 10.2% year over year. The company issued third-quarter EPS guidance of $3.84–$3.88.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $275.70 target price. AbbVie also declared a quarterly dividend of $1.73 per share, representing a 2.8% annualized yield.

MRA Advisory Group raised its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 195.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,883 shares of the company's stock after buying an additional 5,215 shares during the quarter. MRA Advisory Group's holdings in AbbVie were worth $1,984,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after acquiring an additional 3,032,438 shares during the period. State Street Corp boosted its stake in AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company's stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC grew its holdings in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Bank of America Corp DE grew its holdings in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock worth $5,900,617,000 after purchasing an additional 356,394 shares during the period. Finally, Norges Bank bought a new position in shares of AbbVie during the fourth quarter valued at approximately $5,865,055,000. Institutional investors own 70.23% of the company's stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $245.82 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The business has a 50-day simple moving average of $241.96 and a two-hundred day simple moving average of $224.96. The firm has a market cap of $434.31 billion, a price-to-earnings ratio of 69.44, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the prior year, the business earned $2.97 EPS. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ABBV shares. Morgan Stanley reiterated an "overweight" rating and set a $296.00 target price on shares of AbbVie in a report on Monday. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday. BMO Capital Markets raised their price objective on AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday. Finally, Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.70.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source